Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Restructuring Costs (2022 - 2024)

Akebia Therapeutics (AKBA) has disclosed Restructuring Costs for 3 consecutive years, with $58000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Restructuring Costs fell 45.28% to $58000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was -$36000.0, a N/A change, with the full-year FY2024 number at $58000.0, down 67.96% from a year prior.
  • Restructuring Costs was $58000.0 for Q1 2024 at Akebia Therapeutics, up from -$94000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $14.5 million in Q2 2022 to a low of -$94000.0 in Q2 2023.
  • A 3-year average of $2.7 million and a median of $143000.0 in 2022 define the central range for Restructuring Costs.
  • Peak YoY movement for Restructuring Costs: plummeted 100.65% in 2023, then tumbled 45.28% in 2024.
  • Akebia Therapeutics' Restructuring Costs stood at $1.2 million in 2022, then crashed by 107.69% to -$94000.0 in 2023, then surged by 161.7% to $58000.0 in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Restructuring Costs are $58000.0 (Q1 2024), -$94000.0 (Q2 2023), and $106000.0 (Q1 2023).